Showing results (11-20 of 408) with videos related to
Sort By:
Pageof 41
Cancer Biotherapy & Radiopharmaceuticals|May 5, 2005
Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphomaGregory A Wiseman, Thomas E WitzigCurrent Treatment Options in Oncology|April 30, 2004
Waldenström macroglobulinemiaIrene M Ghobrial, Thomas E WitzigTherapeutic Advances in Hematology|April 5, 2013
Initial therapy of mantle cell lymphomaDavid J Inwards, Thomas E WitzigCurrent Treatment Options in Oncology|June 12, 2002
Heavy chain diseaseThomas E Witzig, Dietlind L Wahner-RoedlerPlos One|July 18, 2013
A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signalingGuangzhen Hu, Thomas E Witzig, Mamta GuptaJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Thalidomid: current role in the treatment of non-plasma cell malignanciesShaji Kumar, Thomas E Witzig, S Vincent RajkumarOncotarget|February 6, 2016
Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effectiveJose Caetano Villasboas, Stephen M Ansell, Thomas E WitzigProceedings (Baylor University. Medical Center)|April 2, 2013
Recurrent acute inflammatory demyelinating polyradiculoneuropathy following R-CHOP treatment for non-Hodgkin lymphomaJackson J Liang, Preet P Singh, Thomas E WitzigCA: a Cancer Journal for Clinicians|May 14, 2005
Targeting apoptosis pathways in cancer therapyIrene M Ghobrial, Thomas E Witzig, Alex A AdjeiJournal of Hematology & Oncology|November 25, 2010
Targeted therapy in lymphomaPatrick B Johnston, RuiRong Yuan, Franco Cavalli, et al.Pageof 41